三生国健(688336.SH)：重组抗IL-4Rα人源化单克隆抗体注射液新药上市申请获受理

Core Viewpoint - The company, 3SBio Inc. (三生国健), has received acceptance for its new drug application (NDA) for SSGJ-611, a humanized monoclonal antibody targeting IL-4Rα, from the National Medical Products Administration (NMPA) [1] Group 1 - The product SSGJ-611 is a self-developed and designed humanized monoclonal antibody with a novel amino acid sequence [1] - SSGJ-611 works by specifically binding to IL-4Rα, blocking the signaling of IL-4 and IL-13, which helps alleviate conditions such as atopic dermatitis [1]